{"entity":{"id":"nct06163430","kind":"trial","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","aka":[],"tldr":"A phase 1/2 trial of TERN-701 in chronic myeloid leukaemia, run by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), now recruiting.","summary":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) is a phase 1/2 interventional study registered as NCT06163430 by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 180 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-11-30. Interventions recorded: TERN-701.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06163430","url":"https://clinicaltrials.gov/study/NCT06163430"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06163430","phase":"1/2","setting":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia","sponsor":"Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","enrolled":180,"outcomes":[]},"route":"/trials/nct06163430/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}]}}